Therapeutic efficacy and bone mineral density response during and following a three-month re-treatment of endometriosis with nafarelin (Synarel)

G D Adamson, G. David Adamson, Heinrichs WL, W L Heinrichs, M R Henzl, Milan R. Henzl, Henzl Mr, A A Yuzpe, Albert Yuzpe, Yuzpe AA, Christer Bergquist, Bergquist C, C Bergquist, Jacobson JJ, Jan J. Jacobson, J J Jacobson, Eriksson S, S Eriksson, Staffan Eriksson, Kwei L, Long Kwei, L Kwei, Sandra M. Gilbert, S M Gilbert, Gilbert SM
American journal of obstetrics and gynecology · 1997 · vol. 177(6) , pp. 1413–1418 · doi:10.1016/s0002-9378(97)70084-x · PMID:9423744 · W2146137592
Non-randomised trial OA: closed CC0 ⤵ 8 in-corpus citations
View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by gemini-2.5-flash-lite, 2026-06-28 ⓘ

This study investigated the therapeutic effects and bone mineral density changes in endometriosis patients undergoing three months of re-treatment with nafarelin.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

OBJECTIVE: Our goal was to determine the effects of a repeated course of the gonadotropin-releasing hormone agonist nafarelin on symptoms and signs of endometriosis and lumbar and distal radius bone mineral density. STUDY DESIGN: Forty-five women previously treated for 6 months with nafarelin, who had recurrent symptoms and signs of endometriosis, received 400 mcg/day of nafarelin intranasally for 3 months. Efficacy was evaluated by changes in severity of symptoms and signs. Lumbar bone mineral density was measured by dual-energy x-ray absorptiometry and distal radius bone mineral density by single-photon absorptiometry. Bone mineral density was also measured in 10 control volunteers. RESULTS: Repeated 3-month treatment significantly alleviated recurrent symptoms and signs of endometriosis. Lumbar bone mineral density decreased significantly by a mean of 2% at the end of treatment; this loss was restored within 3 to 6 months after treatment completion. No bone mineral density decline occurred in the radius. Bone mineral density changes in the control group were statistically insignificant. CONCLUSIONS: A repeated 3-month course of nafarelin treatment significantly relieved recurrent endometriotic symptoms and signs without sustained loss of bone mineral density.

My notes (saved in your browser only)

Condition tags

endometriosis

MeSH descriptors

Bone Density Bone Density Endometriosis Endometriosis Hormones Nafarelin Adult Adult Endometriosis Endometriosis Estradiol Estradiol Estradiol Female Female Hormones Hormones Hormones Humans Humans

Citation neighborhood (2-hop)

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. Outer rings show 2-hop neighbours — papers reached through the immediate citers/citees. [ collapse to 1-hop ]

References (15)

Cited by (8)

Source provenance

europepmc
last seen: 2026-10-15T06:08:49.021275+00:00
openalex
last seen: 2026-06-10T17:14:06.276822+00:00
pubmed
last seen: 2026-10-08T22:00:28.864438+00:00
unpaywall
last seen: 2026-10-15T06:24:24.424788+00:00
License: CC0 · commercial use OK